Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $173.88.

A number of equities research analysts have issued reports on the stock. Wedbush increased their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Citigroup lifted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a report on Thursday, February 8th. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a report on Friday. Morgan Stanley reiterated an “equal weight” rating and issued a $116.00 price objective on shares of Ascendis Pharma A/S in a research note on Monday, April 22nd. Finally, Wells Fargo & Company upped their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a research note on Friday.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently modified their holdings of ASND. EverSource Wealth Advisors LLC raised its stake in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 91 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the last quarter. Quadrant Capital Group LLC boosted its position in shares of Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. PNC Financial Services Group Inc. grew its stake in Ascendis Pharma A/S by 1.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 16,384 shares of the biotechnology company’s stock worth $2,064,000 after buying an additional 159 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Ascendis Pharma A/S by 1.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,989 shares of the biotechnology company’s stock worth $1,762,000 after buying an additional 186 shares during the period.

Ascendis Pharma A/S Stock Down 2.8 %

NASDAQ:ASND opened at $137.20 on Friday. Ascendis Pharma A/S has a 52 week low of $83.75 and a 52 week high of $161.00. The stock’s fifty day moving average is $147.11 and its two-hundred day moving average is $127.28. The stock has a market capitalization of $7.99 billion, a price-to-earnings ratio of -14.83 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $0.49. The firm had revenue of $148.62 million for the quarter, compared to analyst estimates of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, sell-side analysts expect that Ascendis Pharma A/S will post -4.15 EPS for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.